Literature DB >> 5001620

Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin.

G G Jackson, L J Riff.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5001620     DOI: 10.1093/infdis/124.supplement_1.s185

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  33 in total

1.  Gentamicin blood levels: a guide to nephrotoxicity.

Authors:  J G Dahlgren; E T Anderson; W L Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1975-07       Impact factor: 5.191

2.  Antimicrobial activity of ceftriaxone compared with cefotaxime in the presence of serum albumin.

Authors:  S K Nath; G A Foster; L A Mandell; C Rotstein
Journal:  Can J Infect Dis       Date:  1995-01

3.  Population pharmacokinetics of arbekacin in burn patients.

Authors:  Jong Hyun Kim; Hyon-Oh Lah; Dong-Seok Yim
Journal:  Eur J Clin Pharmacol       Date:  2008-06       Impact factor: 2.953

Review 4.  Antimicrobial agent therapy for Pseudomonas aeruginosa.

Authors:  J A Korvick; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

5.  Serum levels of gentamicin at peak and trough in neonates and infants.

Authors:  M Shahidullah; M Q Talukder; A K Chowdhury; S Ali; A Rashid
Journal:  Indian J Pediatr       Date:  1991 Mar-Apr       Impact factor: 1.967

6.  Gentamicin dosage in children.

Authors:  M Taylor; C Keane
Journal:  Arch Dis Child       Date:  1976-05       Impact factor: 3.791

7.  Therapeutic drug monitoring.

Authors:  N Buchanan
Journal:  Indian J Pediatr       Date:  1986 Mar-Apr       Impact factor: 1.967

8.  Synergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats.

Authors:  R E Scott; H G Robson
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

Review 9.  Why monitor serum levels of gentamicin?

Authors:  M Barza; M Lauermann
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

10.  Increased aminoglycoside dosage requirements in hematologic malignancy.

Authors:  R G Zeitany; N S El Saghir; C R Santhosh-Kumar; M A Sigmon
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.